## Press Release

Basel, 17. June 2015

# Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery

Genedata and IntelliCyt today announced an alliance that brings together the market-leading strengths of each company to transform screening of suspension cells. The technology alliance integrates the highly-scalable data analytics and workflow capabilities of Genedata Screener® software with the high-throughput (HT) flow cytometry capabilities of the IntelliCyt iQue® Screener system. The integrated solution enables drug discovery researchers to efficiently screen large libraries against suspension cells and multiplex beads in phenotypic drug discovery, antibody screening, immunology, and biomarker research - an industry first.

### Full Potential of Flow Cytometry - Realized

With the novel iQue Screener instrument, throughput in flow cytometry experiments is dramatically increased by 10-to 20-fold over other plate-based flow cytometry approaches. It allows analysis of more than 10,000 cells or beads per second, each with 6 to 15 parameters, resulting in 60,000 to 150,000 data points per second from a given sample.

The challenge: efficient data analysis from the enormous data sets generated across all plates in screening experiments. Genedata software's support of IntelliCyt systems addresses this challenge with standardized data import options, highly scalable analysis workflows, and visualization strategies, all of which enable easy and objective interpretation of high-throughput flow cytometry data in screening experiments.

Supporting the FCS3 data file standard, the Genedata/IntelliCyt solution delivers all the data analysis benefits of Genedata software combined with the speed and efficiency of IntelliCyt iQue systems, enabling:

- Easy import of interactive analysis of 15 or more result parameters across a complete screening campaign for all screening applications including dose response curve fitting.
- Optional import of cell data for in-depth QC from wells to cell populations and back.
- Overall reduction of data analysis time by extending the built-in support for screening to the HT flow technology.
- Reduced errors and enhanced data quality results.
- Removal of human bias with standardized workflows.
- Integration of HT flow technology into the regular screening workflow for results reporting from HT flow directly to the data warehouse without additional integration of data processing pipelines.

"The alliance between Genedata and IntelliCyt underscores our commitment to support all emerging technologies that drive value for our customers," said Dr. Othmar Pfannes, CEO of Genedata. "It's especially exciting to see a screening technology mature and scale to high throughput and that Genedata Screener easily supports yet another technology that empowers researchers to quickly interpret flow cytometry results and optimize result quality."

Please contact us for detailed information!

**Bucher Biotec AG**
Viaduktstrasse 42
4051 Basel

Tel.:    061 269 1111

Email:  info@bucher.ch
www:   http://www.bucher.ch